![](https://endpts.com/wp-content/uploads/2021/05/Rob-Davis-Merck-scaled.jpg)
Merck CEO Rob Davis
Merck emerges as lead bidder in potential Acceleron buyout with deal possible this week — report
With rumors swirling about a potential buyout of biotech Acceleron and its lead PAH drug sotatercept, market watchers have been keeping close tabs on industry …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.